Success Stories: Indian Research Scientist Secures NIW Approval for Cancer Therapeutics Research
Client’s Testimonial:
“I can’t thank enough Chen Group and Belinda for all the help and support. Belinda is the best. She understood the complexity of my situation and provided the best help in a very short time. They are highly skilled and knowledgeable on research in cancer and other diseased conditions to make an overwhelmingly compelling case for the national and global importance of my research. Belinda just needed a rough draft from me that is not even written systematically, not informative fully and organized. She turned that draft into a perfect summary of research and proposed endeavor. Belinda is also thorough in checking consistency, grammatical and technical mistakes in the documents. At the time of preparation, I was going through personal crisis and they understood it and helped me to finish the application in short time with minimal effort from my side. They are very helpful, professional, quick to response and had edited my draft until I am satisfied. I strongly recommend Belinda and Chen group.”
On September 19th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Research Scientist in the field of Biochemistry (Approval Notice).
General Field: Biochemistry
Position at the Time of Case Filing: Research Scientist
Country of Origin: India
State of Residence at the Time of Filing: Virginia
Approval Notice Date: September 19th, 2025
Processing Time: 28 days (Premium Processing Requested)
Case Summary:
We are pleased to share the EB-2 NIW (National Interest Waiver) approval of a research scientist from India. At the time of filing, he was working in the United States, applying his expertise in molecular biology and biochemistry to advance cancer therapeutics. His publication record, growing citations, and peer recognition demonstrated that he was a strong candidate for NIW approval.
Research with Substantial Merit and National Importance
The client’s proposed endeavor focuses on overcoming drug resistance in cancer by targeting key pathways such as Nrf1 and DDI2, which enable tumor cells to withstand proteasome inhibitors. By developing small-molecule inhibitors and designing effective combination therapies, his work contributes to safer and more successful cancer treatments.
Drug resistance remains responsible for most cancer treatment failures, making his research nationally important. His studies support U.S. initiatives like the Cancer Moonshot by advancing therapies that reduce mortality, improve quality of life, and ease the economic burden of chronic disease.
Well Positioned to Advance the Proposed Endeavor
The client holds a Ph.D. in biochemistry and has authored 11 peer-reviewed journal articles, 5 of them as first or co-first author, published in respected outlets such as ACS Central Science, Journal of Cell Biology, International Journal of Molecular Sciences, and Scientific Reports. His research has been cited more than 650 times by independent researchers worldwide, with multiple articles ranked among the top 10 to 20 percent of most cited in their publication years.
He has also advanced the field through methodological innovations. His work on resveratrol-based compounds, STAT3 regulation, and proteasome function has been adopted in studies of cancer biology, neurodegeneration, and drug discovery, underscoring his influence and credibility.
NIW Approval and Outlook
The I-140 NIW petition was filed on August 22, 2025, upgraded to premium processing, and approved on September 19, 2025. USCIS recognized his scholarly record, citation impact, peer review contributions, and the national importance of his proposed endeavor as sufficient to meet the NIW standard.
With NAILG’s support, the client secured NIW approval and is now well-positioned to continue his biomedical research in the United States. His ongoing work promises to contribute to safer, more effective cancer therapeutics, reinforcing U.S. leadership in life sciences and public health.